Rho GTPases: promising cellular targets for novel anticancer drugs.
about
The HPV16 E6 binding protein Tip-1 interacts with ARHGEF16, which activates Cdc42RhoA as a mediator of clinically relevant androgen action in prostate cancer cellsRhoB loss prevents streptozotocin-induced diabetes and ameliorates diabetic complications in miceCAS proteins in normal and pathological cell growth controlComparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatinEndogenous RhoG is dispensable for integrin-mediated cell spreading but contributes to Rac-independent migration.Rho GTPases: Novel Players in the Regulation of the DNA Damage Response?Cooperative anti-invasive effect of Cdc42/Rac1 activation and ROCK inhibition in SW620 colorectal cancer cells with elevated blebbing activityIn situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12CProteolysis of the human DNA polymerase delta smallest subunit p12 by μ-calpain in calcium-triggered apoptotic HeLa cellsMolecular basis for HEF1/NEDD9/Cas-L action as a multifunctional co-ordinator of invasion, apoptosis and cell cycleTargeting Cdc42 with the small molecule drug AZA197 suppresses primary colon cancer growth and prolongs survival in a preclinical mouse xenograft model by downregulation of PAK1 activityIdentification of potential small molecule binding pockets on Rho family GTPasesNovel Activities of Select NSAID R-Enantiomers against Rac1 and Cdc42 GTPasesGRB2 couples RhoU to epidermal growth factor receptor signaling and cell migration.Detecting multivariate differentially expressed genes.The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation.Small molecule targeting Cdc42-intersectin interaction disrupts Golgi organization and suppresses cell motility.RhoB controls coordination of adult angiogenesis and lymphangiogenesis following injury by regulating VEZF1-mediated transcription.Preclinical development of novel Rac1-GEF signaling inhibitors using a rational design approach in highly aggressive breast cancer cell lines.Distinct pigmentary and melanocortin 1 receptor-dependent components of cutaneous defense against ultraviolet radiation.HPV16 E7-dependent transformation activates NHE1 through a PKA-RhoA-induced inhibition of p38alpha.Dynamical modeling of the cholesterol regulatory pathway with Boolean networks.Phosphatase of regenerating liver-3 localizes to cyto-membrane and is required for B16F1 melanoma cell metastasis in vitro and in vivoRac inhibition reverses the phenotype of fibrotic fibroblasts(--)-Xanthatin selectively induces GADD45γ and stimulates caspase-independent cell death in human breast cancer MDA-MB-231 cells.Adaptation to statins restricts human tumour growth in Nude mice.Simvastatin induces apoptosis and alters cytoskeleton in endometrial stromal cellsRhoA/Rho-kinase and vascular diseases: what is the link?Survivin and escaping in therapy-induced cellular senescence.Novel split-luciferase-based genetically encoded biosensors for noninvasive visualization of Rho GTPases.Blockade of protein geranylgeranylation inhibits Cdk2-dependent p27Kip1 phosphorylation on Thr187 and accumulates p27Kip1 in the nucleus: implications for breast cancer therapy.Integrative analysis of transcriptional regulatory network and copy number variation in intrahepatic cholangiocarcinoma.Pleiotropic functions of Rho GTPase signaling: a Trojan horse or Achilles' heel for breast cancer treatment?Multiplexing siRNAs to compress RNAi-based screen size in human cells.Rho Kinase ROCK2 Mediates Acid-Induced NADPH Oxidase NOX5-S Expression in Human Esophageal Adenocarcinoma Cells.Lymphangioleiomyomatosis: what do we know and what are we looking for?Simvastatin decreases invasiveness of human endometrial stromal cells.Lovastatin prevents bleomycin-induced DNA damage to HepG2 cells.Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans
P2860
Q24313916-DD482EF4-81DE-4ADD-952A-05C376473776Q24618899-07A49928-1C52-445C-89CC-57A8FBD86EB2Q24628619-524CE4B9-417B-4428-B114-0093AD0A1584Q24630247-3A9DCD01-31BF-4602-AFBD-C6F6B14A4B0AQ24646870-714A1630-F511-45BC-8E59-A1048F53700BQ24655225-EBE1168B-D2AD-475B-AE4D-5D12287EA280Q26782005-71881C81-BA1D-4E67-928E-07AD02BC4D76Q27312206-CE6E0CAC-28D1-4850-B078-10010B1BFA7BQ27684047-BB122DA9-2E9A-4EB4-9625-A415A8219D22Q28237256-54A7DC5D-3897-4B4A-951A-6D10474A91A7Q28241105-29DD7AF0-1A3B-4269-A795-9815D4770313Q28302802-C7F13056-60AB-4045-A915-4F6569452CCEQ28481320-222E9D6A-EDB3-49FA-8BCE-1B7B8C0F4689Q28550876-53B1EE87-77BD-4E15-AFAD-75D424769238Q30155572-CC64C3EA-DD97-4F02-9E53-6CC6D9D86111Q30479535-D7ED4C84-067D-466C-B364-452E7BA72F89Q30484934-FBCFC09C-6908-4D9C-ABCB-8104F4B3AB17Q30533280-2BB55242-9CFE-4206-83A2-028D3DC5B510Q30560112-E6D246D1-4842-43F3-B797-3C6D5EE7CDDBQ31140123-EFCACFF7-3354-4106-AE08-59059BD9654AQ33269159-3D010EF2-61D4-43C9-A080-EA0339E9A28CQ33379617-14BA547C-BFEF-4577-BC73-93675AFF1633Q33386247-1EDEBDA7-4741-48E7-B3C1-4669535977B2Q33408806-168036F0-6FDE-4418-83C7-D096D134995AQ33510140-25534336-A59C-461A-B7AF-BFA0E4171632Q33872756-35C8FE17-9C82-4A8D-9297-B885EBC1ADDCQ34080247-5771B2D0-D299-4390-A8B6-DDB860FC61ECQ34086658-0690FEED-B8C4-46D7-8B1E-7495BEF6622CQ34378293-3E127E8B-ED2F-4AFF-86EC-A82320074DADQ34400375-16CA78E7-1760-442A-AE39-CCF3EE23A8C2Q34685766-7CCABCD2-B160-443D-B3F5-40E10F98800EQ34940620-3584E979-15D4-4364-A099-FE033C2D38BDQ35181521-D2453DDA-FDCF-4160-A08C-BE29CB8162EDQ35287780-3D0104BD-AC16-4145-9B01-3B44382022A9Q35829326-0C57DE7B-11A1-4F12-B358-958891D7E4F0Q35931392-75854938-0301-4F6E-9B9D-8F97932BC169Q36067383-8CA5CBE5-7262-42FE-9465-4ABD92DCD20BQ36121605-0BC98C2D-2972-4FC1-A404-626555E0D6D8Q36230902-1A365D0A-F4FD-408F-BB85-B0705DE9BF3BQ36330644-F4877828-8E22-4736-B130-D99FB9D321A7
P2860
Rho GTPases: promising cellular targets for novel anticancer drugs.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Rho GTPases: promising cellular targets for novel anticancer drugs.
@ast
Rho GTPases: promising cellular targets for novel anticancer drugs.
@en
type
label
Rho GTPases: promising cellular targets for novel anticancer drugs.
@ast
Rho GTPases: promising cellular targets for novel anticancer drugs.
@en
prefLabel
Rho GTPases: promising cellular targets for novel anticancer drugs.
@ast
Rho GTPases: promising cellular targets for novel anticancer drugs.
@en
P1476
Rho GTPases: promising cellular targets for novel anticancer drugs.
@en
P2093
Bernd Kaina
Gerhard Fritz
P356
10.2174/156800906775471752
P577
2006-02-01T00:00:00Z